Background: Breast cancer currently affects more than two million women worldwide, and its incidence is steadily increasing. One of the most essential factors of invasion and metastasis of breast cancer cells is angiogenesis and non-angiogenic vascularization. Lenvatinib and Regorafenib share the same anti-angiogenic effect by inhibiting vascular endothelial growth factor receptors (VEGFRs subtypes 1 to 3) and have been approved for treating different types of cancer. Methods: We investigated Lenvatinib and Regorafenib effects on a well-established in-vitro model of breast cancer using MCF-7 (estrogen, progesterone receptor-positive, and HER2-negative), MDA-MB-231 (triple negative), as well as Human Umbilical Vascular Endothelial Cell line (HUVEC) cell lines. We performed the cell viability assay on four groups of cells, which included a control group, a Lenvatinib treated only group, a Regorafenib treated only group, and a group treated with a combination of both drugs at 24, 48, and 72 h. Data were analyzed as means ± standard deviation, and the drug–drug interactions with Compusyn software. Cellular migration assay, tube formation assay, and Western blots were conducted to determine the functional and the protein expression of downstream signals such as Caspase-9, anti-apoptotic Survivin, P-ERK, and total-ERK in the control and treatment groups. Results: MCF-7 cells showed a reduction in cell survival rates with higher dosing and longer incubation periods with each drug and with the combination of drugs. A synergistic interaction was identified (CI < 1) with both drugs on MCF7 at different dose combinations and at a higher dose in MDA-MB-231 cells. Furthermore, there was a marked decrease in the anti-angiogenic effect of both drugs in tube formation assay using MDA-MB-231 cells and survivin protein expression in MCF-7, and those antitumor markers showed a better outcome in drug combination than the use of each drug alone. Conclusion: Our result is the first to report the synergistic anti-angiogenic potential of combination therapy of Lenvatinib and Regorafenib. Therefore, it shows their therapeutic potential in breast cancer, including the aggressive types. Further studies are warranted to confirm and explore this therapeutic approach.

Background: Heat strokes are predictable and preventable, so sufficient public awareness of the condition and preventative practices are essential in hot and humid countries such as the United Arab Emirates (UAE). This study aims to assess the level of awareness (knowledge, prevention, and management) of heat stroke among UAE residents. Methods: Survey-based study of a random sample of adults (?18 years) in four different cities of UAE. The questionnaire included 37 questions on knowledge and practices. Correct answer was equal to one point and total scores were calculated. The average of participants’ total scores was taken as cut-off point. Multivariate logistic regression was used to identify associated factors with below-average awareness. Results: A total of 402 people participated in the study, with age average 33±12 years and 48.5% were female. Only 1 person achieved a perfect score and 0.7%, 10%, and 17.7% achieved above average scores in knowledge, practices, and management, respectively. Seven percent of participants had never heard of a heat stroke before. A third of participants (32%) did not know that severe heat strokes can lead to death. Males are at higher risk of having a poor level of knowledge (Odds ratio [OR]=1.65; 95% confidence interval [95%CI]=1.10-2.47). The older the population the poor was the knowledge about heat stroke (OR=1.39, 95%CI=1.03-1.89). Conclusion: The results of this study show that a huge proportion of the population in the UAE does not have sufficient knowledge about heat stroke, its prevention, and management. Governmental institutes should increase awareness of heat stroke.

Prolonged cholestasis is a rare complication of hepatitis A infection, characterized by a protracted, indolent course with persistent symptoms of pruritus and malabsorption lasting for several months. A 14-year-old girl, previously treated for acute hepatitis A, presented with yellowing of the eyes. An evaluation of her liver function revealed conjugated hyperbilirubinemia, and a liver biopsy confirmed hepatitis with cholestasis. Fortunately, she responded well to conservative treatment and recovered successfully.

In the pediatric population, headache is a common presenting symptom, and migraine is often the diagnosis. A hemiplegic migraine is characterized by an aura and sudden-onset weakness on one side of the body that usually resolves without causing any permanent neurological damage. In this case, we present a seven-yearold male child with a known case of proximal tubular dysfunction (homozygous mutation in the SLC4A4 gene) who presented to the emergency department with a one-day history of weakness on the right side of his body. A few hours after being discharged from the hospital, he began complaining of a severe headache on the left side, accompanied by photophobia, phonophobia, and high fever. Radiology scans and laboratory workup were unremarkable, and encephalitis was ruled out. He was later diagnosed with hemiplegic migraine based on his history and clinical presentation.

How to cite this erratum